Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 mars 2019 07h00 HE | Source: Biogen Inc.

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

CAMBRIDGE, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced the decision to discontinue the global Phase 3 trials, ENGAGE and...
12 mars 2019 03h00 HE | Source: Biogen Inc.

Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm

Approximately 800 employees at Hillerød site expected to continue employment under Fujifilm ownership Biogen will enter into manufacturing services agreements with Fujifilm to supply TYSABRI® and...
04 mars 2019 02h00 HE | Source: Biogen Inc.

Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

Biogen to acquire Nightstar Therapeutics for $25.50 per share Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited...
28 févr. 2019 07h30 HE | Source: Biogen Inc.

Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy

SPINRAZA is the standard of care for treating infants, children and adults with spinal muscular atrophy, a rare, genetic neuromuscular disease SPINRAZA was approved under the China National Medical...
25 févr. 2019 07h30 HE | Source: Biogen Inc.

Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA)...
04 janv. 2019 07h30 HE | Source: Biogen Inc.

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

C4T’s targeted protein degradation platform provides a novel approach to neuroscience drug discovery and development, complementing Biogen’s broader research and development efforts across multiple...
04 janv. 2019 07h30 HE | Source: Biogen Inc.

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other...
03 janv. 2019 07h30 HE | Source: Biogen Inc.

First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis

Study will provide the first randomized, controlled efficacy and safety data of every-six-week dosing for natalizumab CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- The first patient has been...
17 déc. 2018 07h30 HE | Source: Biogen Inc.; Alkermes plc

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

DUBLIN, Ireland and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc. (Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application...
06 déc. 2018 07h30 HE | Source: Biogen Inc.; Ionis Pharmaceuticals, Inc.

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067Biogen plans to advance BIIB067 to a pivotal clinical studyBiogen paid Ionis Pharmaceuticals a $35 million...

Page précédente